AC
NBIX icon

Allstate Corporation’s Neurocrine Biosciences NBIX Stock Holding History

Allstate Corporation’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1M Buy
12,444
+95
+0.8% +$14.1K 0.02% 458
2026
Q1 		$1.63M Buy
12,349
+5,195
+73% +$689K 0.02% 600
2025
Q4 		$1.01M Buy
7,154
+3,786
+112% +$548K 0.01% 521
2025
Q3 		$473K Buy
+3,368
New +$456K 0.01% 529
2025
Q2 		– Sell
-4,930
Closed -$545K – 433
2025
Q1 		$545K Buy
4,930
+2,021
+69% +$256K 0.02% 487
2024
Q4 		$397K Buy
+2,909
New +$360K 0.01% 539
2023
Q1 		– Sell
-4,215
Closed -$503K – 443
2022
Q4 		$503K Buy
4,215
+1
+0% +$117 0.02% 495
2022
Q3 		$448K Buy
4,214
+623
+17% +$63.2K 0.01% 518
2022
Q2 		$350K Buy
+3,591
New +$331K 0.01% 556
2021
Q4 		– Sell
-3,522
Closed -$338K – 754
2021
Q3 		$338K Sell
3,522
-271
-7% -$25.6K 0.01% 601
2021
Q2 		$369K Buy
3,793
+250
+7% +$24K 0.01% 600
2021
Q1 		$345K Sell
3,543
-1,201
-25% -$126K 0.01% 638
2020
Q4 		$455K Buy
4,744
+1,323
+39% +$128K 0.01% 536
2020
Q3 		$329K Sell
3,421
-592
-15% -$68.5K 0.01% 546
2020
Q2 		$490K Sell
4,013
-172
-4% -$19K 0.02% 442
2020
Q1 		$362K Sell
4,185
-8,800
-68% -$861K 0.01% 438
2019
Q4 		$1.4M Hold
12,985
– – 0.03% 373
2019
Q3 		$1.17M Buy
12,985
+210
+2% +$19.6K 0.02% 371
2019
Q2 		$1.08M Buy
+12,775
New +$1.05M 0.02% 380

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Allstate Corporation's NBIX Position: Q2 2026 in Review

Allstate Corporation increased its Neurocrine Biosciences (NBIX) stake by 0.77% in Q2 2026, buying an estimated $14.1K and bringing the position to 12,444 shares worth $2.1M. The position accounts for 0.02% of the portfolio, ranked #458.

Allstate Corporation first reported a position in NBIX in Q2 2019 and has held it in 19 quarters since. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Allstate Corporation held 12,444 shares of Neurocrine Biosciences worth $2.1M as of Q2 2026.
  • Allstate Corporation bought 95 Neurocrine Biosciences shares in Q2 2026, an estimated $14.1K.
  • Neurocrine Biosciences made up 0.02% of Allstate Corporation's portfolio in Q2 2026, its #458 holding.
  • Allstate Corporation first reported a position in Neurocrine Biosciences in Q2 2019 and has held it in 19 quarters since.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.